THE FIRST STUDY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS LED TO SUSTAINED CLINICAL RESPONSE AND INHIBITION OF RADIOGRAPHIC PROGRESSION AT 52 WEEKS: THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY

被引：2

作者：

Emery, P. ^{[1
]}

Bingham, C. O. ^{[2
]}

Burmester, G. -R. ^{[3
]}

Bykerk, V. P. ^{[4
]}

Furst, D. E. ^{[5
]}

Mariette, X. ^{[6
]}

van der Heijde, D. ^{[7
]}

Tatla, D. ^{[8
]}

Arendt, C. ^{[9
]}

Mountian, I. ^{[9
]}

VanLunen, B. ^{[8
]}

Weinblatt, M. ^{[10
]}

机构：

[1] Univ Leeds, Leeds, W Yorkshire, England

[2] Johns Hopkins Univ, Baltimore, MD USA

[3] Charite Univ Med Berlin, Berlin, Germany

[4] Hosp Special Surg, Weill Cornell Med Coll, New York, NY 10021 USA

[5] Univ Calif Los Angeles, Los Angeles, CA USA

[6] Univ Paris Sud, Hop Univ Paris Sud, AP HP, Paris, France

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] UCB Pharma, Raleigh, NC USA

[9] UCB Pharma, Brussels, Belgium

[10] Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷

关键词：

D O I：

10.1136/annrheumdis-2015-eular.1493

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0164

引用

页码：712 / 712

页数：1

共 50 条

[1] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C. O.
Burmester, G. -R.
Bykerk, V. P.
Furst, D. E.
Mariette, X.
Purcaru, O.
Coteur, G.
VanLunen, B.
Weinblatt, M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 712 - 713
[2] IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C-EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C.
Burmester, G.
Bykerk, V
Furst, D.
Mariette, X.
Purcaru, O.
Coteur, G.
Vanlunen, B.
Weinblatt, M.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A707 - A708
[3] Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
Weinblatt, Michael
Bingham, Clifton
Burmester, Gerd
Bykerk, V. P.
Furst, Daniel E.
Mariette, Xavier
van der Heijde, Desiree
Tatla, Daljit
Arendt, Catherine
Mountian, Irina
VanLunen, Brenda
Emery, Paul
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[4] IMPROVEMENTS IN WORKPLACE AND HOUSEHOLD PRODUCTIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN DMARD-NAIVE PATIENTS WITH SEVERE, ACTIVE AND PROGRESSIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE C -EARLY RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3 STUDY
Emery, P.
Bingham, C.
Burmester, G. R.
Bykerk, V. P.
Furst, D.
Mariette, X.
Purcaru, O.
VanLunen, B.
Weinblatt, M.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A710 - A710
[5] Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Emery, P.
Bingham, C. O., III
Burmester, G. R.
Bykerk, V. P.
Furst, D. E.
Mariette, X.
van der Heijde, D.
van Vollenhoven, R.
Arendt, C.
Mountian, I.
Purcaru, O.
Tatla, D.
VanLunen, B.
Weinblatt, M. E.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 96 - 104
[6] The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression
Atsumi, Tatsuya
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Yamanaka, Hisashi
Ishiguro, Naoki
Tanaka, Yoshiya
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Yasuda, Shinsuke
Yamanishi, Yuji
Kita, Yasuhiko
Matsubara, Tsukasa
Iwamoto, Masahiro
Shoji, Toshiharu
Okada, Toshiyuki
van der Heijde, Desiree
Miyasaka, Nobuyuki
Koike, Takao
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) : 75 - 83
[7] Early Response As a Predictor of Long-Term Remission in DMARD-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Weinblatt, Michael
Bingham, Clifton
Burmester, Gerd
Bykerk, V. P.
Furst, Daniel E.
Mariette, Xavier
van der Heijde, Desiree
Tatla, Daljit
Arendt, Catherine
Mountian, Irina
VanLunen, Brenda
Emery, Paul
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[8] The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression.
Atsumi, Tatsuya
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Yamanaka, Hisashi
Ishiguro, Naoki
Tanaka, Yoshiya
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Shoji, Toshiharu
Togo, Osamu
Okada, Toshiyuki
van der Heijde, Desiree M.
Miyasaka, Nobuyuki
Koike, Takao
[J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1078 - S1079
[9] Rapid Onset of Response Observed with Certolizumab Pegol in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Efficacy and Safety Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Bi, Liqi
Li, Yuhui
He, Lan
Xu, Huji
Gu, Jieruo
Wang, Guochun
Zhang, Zhiyi
Liu, Yi
Boehnlein, Marion
Dunkel, Jochen
Shao, Jing
Harris, Kristina
Li, Zhanguo
[J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
[10] Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
Haagsma, CJ
VanRiel, PLCM
DeJong, AJL
VandePutte, LBA
[J]. BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 (10): : 1082 - 1088

← 1 2 3 4 5 →